Effective antiretroviral therapy has resulted in a close to normal life expectancy for people living with HIV. This has led to a shift in the age distribution of women living with HIV in the UK, with one in three attending for HIV care estimated to be aged 45-56 years in 2014. The lack of experience of many HIV physicians in managing menopause, and the perceived complexity of managing menopause in women living with HIV by general practitioners means that many women are unable to access appropriate care and support. This is aggravated by the relative paucity of data on menopause in women living with HIV and conflicting results in this field, for example with regard to age of onset of menopause and symptomatology experienced. Furthermore, women living with HIV have unique considerations such as potential interactions between antiretroviral therapy and menopause hormone therapy (previously called hormone replacement therapy) and other physiological concerns such as a multifactorial propensity towards decreased bone mineral density and potentially increased cardiovascular risk. On the whole, menopause hormone therapy is probably underutilised in this group of women due to perceived concerns around drug-drug interactions, as well as fears shared with women in the general population about menopause hormone therapy. Menopausal women should be given adequate information on symptomatology, lifestyle modification and treatment options including menopause hormone therapy. Furthermore, a holistic approach which considers the increased burden of poor mental health in this population is essential.
Introduction
The population of women living with HIV (WLHIV) in the UK is aging, creating an increase in the number of women transitioning through the menopause. 1 The lack of research data and conflicting results on the experiences and management of the menopause in WLHIV makes clinical management challenging. This is complicated in some cases by a lack of ownership of the management of these women, who end up falling between HIV physicians and general practitioners (GPs). 2 Generally, HIV specialists have little or no experience in managing menopause and GPs may have concerns over drug-drug interactions or missing an HIV-related illness.
3 It is of little surprise then, that many women find themselves caught between primary care and tertiary HIV services without their menopause needs being met. 2 The purpose of this review article is to highlight and consolidate existing data as well as to provide insight into general and unique management considerations in WLHIV.
HIV in the UK
Advances in antiretroviral therapy (ART) have resulted in improvements in survival, such that successfully treated HIV-positive individuals now have a near normal life expectancy. This in turn has shifted the age distribution of people living with HIV in the UK. 4 Increasing numbers of older women are living with HIV, with one in three attending for HIV care in the UK in 2014 estimated to be aged 45-56 years. 5 As life expectancy in WLHIV increases, comorbidities such as osteoporosis and cardiovascular disease (CVD) also become increasingly important.
Menopause epidemiology in the UK
The average age of natural menopause in the UK is 51 years, although this varies by ethnicity. 6 Menopause symptoms such as hot flushes, sleep disturbance and mood changes are common in the general population and experienced by 85% of women. 7 A recent cohort study from America has demonstrated a median duration of vasomotor symptoms of 7.4 years, continuing for an average of 4.5 years beyond the final menstrual period which is longer than previously thought. 8 Studies have shown that factors such as ethnicity and socioeconomic status affect reporting, duration and experience of menopausal symptoms 9 ; however, menopause symptoms have consistently been shown to have a negative impact upon women's perceived health, quality of life and their performance both at work and within relationships. [10] [11] [12] Does HIV affect the menopause?
There are inherent difficulties in studies of the menopause including the fact that there is no unifying definition or specific biochemical marker. A further confounder is the subjective nature of women's experiences which may be difficult to separate from those related to other chronic medical conditions. WLHIV have higher rates of irregular menstrual bleeding 13 the causes of which are multifactorial and may not always be related to menopause.
Age at menopause
Data on the association between HIV and earlier age at menopause are conflicting. de Pommerol et al. 14 reported that 12% of postmenopausal HIV-infected women sampled had experienced premature menopause. Several studies support this, suggesting WLHIV may transition through menopause at an earlier age than their HIV-negative counterparts. [15] [16] [17] However, factors such as substance misuse and low body weight are associated with an earlier menopause and are common in WLHIV. [14] [15] [16] Other studies have not shown a difference in age at menopause between HIV-positive and HIV-negative women. 18, 19 Studies looking into associations between age at menopause and HIV-related factors such as viral load, CD4 count and use of ART are also conflicting, with some reporting no association, 19 and others reporting current low CD4 cell count as a risk factor.
14, 15 Clark et al. 20 found low CD4 count to be a significant variable when comparing groups of anovulatory versus ovulatory WLHIV. However, in this small study of only 33 women, the authors state that stored serum samples were tested for progesterone and follicle stimulating hormone (FSH) levels from a subset of women participating in the Adult AIDS Clinical Trials Group (ACTG) and may not have been correctly timed.
Gonadal dysfunction
Gonadal dysfunction in men living with HIV is well described 21 ; however, there are fewer data for WLHIV. A recent study has shown anti-Mullerian hormone (AMH) levels to be a reliable indicator of menopausal age in HIV-positive women. 22 One study of 3562 women (WLHIV n ¼ 2621, and HIV-negative women n ¼ 941) demonstrated lower levels of AMH in WLHIV with CD4 count being a strong and independent predictor of AMH in both HIV-negative women and WLHIV. AMH levels were 15.7% lower in women with an undetectable RNA viral load and 25.6% lower in women with a detectable RNA viral load. However, after adjustment for CD4 count and age, AMH levels were found to be higher in HIV-positive women. The authors postulate that this might be linked to lymphocyte activation and the effect of inflammatory mediators on ovarian signalling and granulosa cell function. 23 Possible factors implicated in ovarian dysfunction in WLHIV include opportunistic infections and effects of the virus itself on the ovaries and the pituitary gland. Furthermore, given that HIV infection is increasingly understood to be associated with persistent inflammation, it could be hypothesised that effects on the neuroendocrine axis may alter both the natural history and symptomatology of menopause in WLHIV. 24 
Symptomatology
Menopausal symptoms such as hot flushes, sleep disturbance and mood changes are common in the general population and experienced by 85% of women. 7 The data on symptomatology in WLHIV are mixed. One study showed no association between HIV status and symptoms, including vaginal dryness and hot flushes in women in Brazil. 25 Additionally, a comparison between HIV-positive and negative women in America found no difference in the prevalence of hot flushes or vaginal dryness between the two groups. 26 Others, however, do suggest an association with HIV-positivity and increased hot flushes 27 and mood change. 28 A recent study from Nigeria showed HIV infection to be associated with severe menopausal symptoms. 29 A recent study of 140 women from one centre in the UK, found WLHIV age 45 years and older had higher anxiety scores and severe depression compared to WLHIV who were younger than 45 years of age. 30 In the same study, despite recording distressing symptoms such as flushes, urinary incontinence, decreased sexual desire and back pain in the Menopause Specific Quality in Life questionnaire (MENQOL), 35 of the 57 older women had not sought help for their symptoms.
There is added uncertainty with regard to symptom management in WLHIV, as the aetiology may be unclear, with evidence that symptoms of menopause are often misattributed by both patients and clinicians to HIV-related illness or side effects of ART. 18 An important consideration in HIV-negative women is that menopause-associated vaginal atrophy may contribute to increased risk of HIV acquisition. 31 
Does menopause affect HIV?
Estrogen is known to have immunomodulatory effects; however, of the limited data available, no studies have shown evidence of estrogen deficiency, i.e. menopausal state, affecting CD4 count or response to ART. 32, 33 Patterson et al. 34 studied 267 HIV-infected racially and ethnically diverse women (220 pre-menopausal and 47 post-menopausal) and demonstrated that the median change in absolute CD4 cell counts and percentages did not differ between pre-and postmenopausal women after 96 weeks of ART). There were also no differences between pre-and postmenopausal women in the proportions achieving plasma HIV RNA viral loads <50 copies/mL after 96 weeks of combination antiretroviral therapy (cART) or when adjusted for pre-cART HIV viral loads.
A small number of studies have attempted to determine whether menopause status affects cervical shedding of HIV, thereby potentially increasing the risk of transmission. A study of ectocervical tissue from hysterectomised pre-and post-menopausal women, in which tissue samples were infected ex vivo with HIV-1, found 100% of post-menopausal samples had a higher RNA transcription compared to background compared to 60% in pre-menopausal samples consistent with enhanced viral replication in the post-menopausal group. 35 Melo et al. 36 in a cross-sectional study of pre-and post-menopausal, HIV-positive women in Brazil, using cervicovaginal lavages of WLHIV, showed no association between menopausal status and in vivo cervicovaginal HIV-RNA viral shedding. As expected, the degree of shedding was associated with plasma viral load and vaginal pH.
Physiological and pharmacological considerations of menopause in WLHIV Cardiovascular disease (CVD)
CVD is the leading cause of death in women older than 60 years, accounting for 46% of deaths in this group. 37 Early menopause (before age 45) has been found to be associated with an increased risk of CVD in the general population. 38 It is known that rates of CVD are higher in WLHIV compared to control groups; 39 however, there are no randomised controlled studies comparing CVD outcomes in menopausal WLHIV with HIVnegative women nor with HIV-positive men. While cohort studies suggest that women with already established CVD who receive MHT have poorer outcomes than those who do not, NICE guidelines recommend that this is not a contraindication to MHT, if these risk factors are optimally managed. 40 
Venous thromboembolism
HIV infection is associated with a 2 to 10-fold increased risk of venous thromboembolism (VTE), for multifactorial reasons. 41, 42 These include acquired protein S and C deficiency, low CD4 count and opportunistic infections. Virtually no data exist on VTE risk in women with wellcontrolled HIV disease on cART, or on the risk of VTE in WLHIV on MHT. Transdermal estrogen preparations are associated with a lower risk of VTE than oral preparations so are preferable in WLHIV.
Drug distribution
Alterations in drug pharmacokinetics that occur as a consequence of aging result in changes in volume distribution and renal and hepatic clearance. Two small studies showed no difference in plasma levels of two commonly used antiretrovirals, tenofovir and raltegravir, between pre-and post-menopausal woman. 43, 44 However, there are few data in this area.
Bone mineral density (BMD)
Increasing age and, in particular, the post-menopause are the two most important factors predisposing to low BMD and osteoporosis. However, HIV infection itself has been shown to contribute to bone loss. 45, 46 A metaanalysis has shown that HIV infection is associated with a 6.4-fold increased risk of osteopenia/low BMD and a 3-fold increased risk of osteoporosis. 47 Certain antiretrovirals (ARVs) have been implicated in changes in BMD and indeed, initiation of ART may be associated with a reduction in BMD in the first few years of use; however, this has been shown to stabilise in the long term. 48 Agents such as tenofovir disoproxil fumarate have demonstrated a negative effect on BMD 49 but data are conflicting on the effect of tenofovir on risk of fracture. The new tenofovir prodrug, tenofovir alafenamide, has little impact on bone density and is associated with recovery of previously lost BMD. 50 Beyond HIV infection, risk factors such as cigarette smoking, alcohol use, African-American or Hispanic ethnicity, decreased body mass index, vitamin D deficiency, chronic steroid use, amenorrhea, and hypogonadism are more prevalent in WLHIV. 51 Studies have tried to examine the extent to which low BMD in HIV is explained by low body weight and smoking, and the role of HIV in progression to low BMD; however, many aspects of the relationship between HIV and low BMD remain unclear. 52 
Mental health and menopause
A range of mental health diagnoses including anxiety, low mood and clinical depression may occur at any stage of the menopause. The perimenopause is associated with a two to four-fold increased risk of depression. 53 Maki et al. 54 compared WLHIV (n ¼ 835) with a control group of HIV-negative women (n ¼ 335) and found no significant difference in prevalence of depression between the two groups during menopause. Amongst the HIV-positive cohort, lower CD4 count (<200 cells/mm
3 ) was associated with depression, whereas cART adherence was associated with a lower rate of depression. A limitation of the study is the lack of information regarding past mental health history, as recognised by the authors. This is important as the prevalence of depression amongst PLHIV is higher than the general population. 55 Are there interactions between ARV and menopause hormone therapy (MHT)?
Randomised controlled trials have clearly demonstrated a beneficial effect of MHT on vasomotor symptoms and bone health. 56, 57 Some practitioners may be reluctant to provide MHT to women with HIV for fear of worsening their HIV disease, or because of concerns regarding toxicity, increased pill burden, and/or drug-drug interactions with ART. 3 There is a paucity of data on the utility and safety of MHT in WLHIV and on interactions with ART. However, data do exist on interactions between hormonal contraceptives and ART, some of which might be extrapolated to MHT based on an understanding of the pharmacokinetics of ARVs and reproductive hormones. 58 HIV protease inhibitors (PIs), cobicistat and non-nucleoside reverse transcriptase inhibitors may affect menopause hormone levels because of their effects on the cytochrome P450 (CYP) pathways, shared by reproductive hormones. It may therefore be necessary to titrate hormone levels to achieve the desired therapeutic effect or limit toxicity. Newer ARV agents such as integrase inhibitors do not have significant interactions with reproductive hormones and where appropriate may be substituted for interacting ARVs in women wishing to commence MHT.
Management of menopausal WLHIV
Menopausal WLHIV should be given adequate information on symptomatology, lifestyle modification and treatment options including MHT which can alleviate vasomotor symptoms and low mood as well as having a beneficial effect on bone health. There are no recent data on the number of women in the UK taking MHT. The 2015 NICE guideline costing report bases its calculations on an estimate of 17% of women over the age of 50 with menopausal symptoms. 59 Few data exist on the use of MHT in WLHIV; however two studies, one from the US and one from the UK give a figure of 10%. 60, 61 Therefore, MHT is likely to be underutilised in WLHIV in the UK 62 and should be considered for those who might benefit from it. Discussion with an HIV physician or pharmacist about potential drugdrug interactions is encouraged, but should not be seen as an absolute barrier to the provision of MHT to WLHIV who require it.
Women should be managed according to national guidance [NICE Menopause Guideline; National Osteoporosis Guideline Group (NOGG); British HIV Association (BHIVA) Guidelines] 40, 52, 63 with the use of appropriate assessment tools.
Conclusion and future research
The evidence base is lacking in many areas around managing menopause in WLHIV, including longterm safety and efficacy of MHT, drug-drug interactions between MHT and ART, the potential role of psychosocial interventions, and the impact of the menopause transition on the quality of life in WLHIV. The updated UK guidelines on sexual and reproductive health for PLHIV will include a new section on the management of menopause in WLHIV. The PRIME study, 64 a longitudinal study of 1000 WLHIV in the UK, hopes to address some of these issues. In the interim, a multidisciplinary approach with clear lines of communication between GPs and HIV physicians is paramount to ensure the well-being of WLHIV transitioning through the menopause.
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